Jonathan Hangi Ndungo

Jonathan Hangi Ndungo

Auto-generated profile, based on publicly available information

Jonathan Hangi Ndungo


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2026 in Evidence Synthesis in Healthcare Connect
Verified
Journal Article
Open access
PDF file
Cheuyem Lekeumo Fabrice ZobelCheuyem Lekeumo Fabrice Zobel
Cheuyem Lekeumo Fabrice Zobel
CAConstantine Tanywe Asahngwa
Constantine Tanywe Asahngwa
WBWilliam Ndjidda Bakari
William Ndjidda Bakari
CAChabeja Achangwa
Chabeja Achangwa
JGJessy Goupeyou-Youmsi
Jessy Goupeyou-Youmsi
JNJonathan Hangi Ndungo
Jonathan Hangi Ndungo
Introduction: Monkeypox (Mpox) is an endemic disease in the Democratic Republic of Congo (DRC). After five decades of outbreaks, gaps still remain in understanding clinical patterns and coinfections with varicella-zoster virus (VZV) and human immunodeficiency virus (HIV) in this high-burden setting. This systematic review and meta-analysis were conducted to synthesize data on Mpox clinical presentation and coinfection trends in the Democratic Republic of the Congo. Estimating the burden of VZV and HIV coinfections will help informing decision maker during the fight against this outbreak. Methods: This study was conducted by systematically extracting data from online databases including PubMed, ScienceDirect, and Google Scholar. The pooled estimate VZV and HIV coinfection rates were calculated using fixed and random-effects models. Subgroup analyses were performed by time period, region, study design, setting, and participant characteristics. Results Among a total of 1,841 confirmed Mpox cases, VZV coinfection was 9.69% (95% CI: 1.33–18.06; n = 8), with higher rates in Kivu (33.33%) compared to Equateur (11.10%). The VZV pooled prevalence rate among 64,131 suspected Mpox cases was 16.73% (95% CI: 5.36-28.10; n = 8), with I2 = 99.4% (p ˂ 0.001). The pooled estimate of HIV coinfection rate was low (0.52%, 95% CI: 0.18–0.87) at national level but elevated in South Kivu (1.64%). Among confirmed cases, rash (99.97%), painful lesions (78.17%), and Malaise (77.14%) were the main clinical presentation and this highlights their diagnostic importance in the case definition. A similar clinical pattern of Mpox was observed among suspected cases, were almost all recorded cases reported rash (99.43%) and fever (98.91%). Heterogeneity was high (I² > 90%) for most study outcomes. Conclusion: The substantial VZV coinfection prevalence and distinct regional HIV patterns highlight critical gaps in syndromic surveillance and the urgent need for integrated diagnostic strategies. This review confirms that Mpox in the DRC presents with near-universal rash, underlining their centrality to case definitions. These findings provide essential evidence for strengthening frontline detection and tailored outbreak response in endemic zones.

1 July 2026 in Bulletin of the National Research Centre
Verified
Journal Article
Open access
Cheuyem Lekeumo Fabrice ZobelCheuyem Lekeumo Fabrice Zobel
Cheuyem Lekeumo Fabrice Zobel
AZArmel Zemsi
Armel Zemsi
JNJonathan Hangi Ndungo
Jonathan Hangi Ndungo
CAChabeja Achangwa
Chabeja Achangwa
DTDavy Roméo Takpando-Le-Grand
Davy Roméo Takpando-Le-Grand
SNSaralees Nadarajah
Saralees Nadarajah
Background: Mpox, caused by the Mpox virus, is a zoonotic disease historically endemic in Central and West Africa. Despite the Democratic Republic of Congo (DRC) carrying the highest Mpox burden, the literature lacks comprehensive data on long-term trends and geographic disparities inMpox% disease severity and mortality, highlighting a significant research gap. Understanding severity and mortality trends is critical for global control efforts. Methods: This systematic review and meta-analysis followed PRISMA guidelines to synthesize evidence on Mpox severity and mortality in the DRC from 1970 to 2024. We searched PubMed, ScienceDirect, Scopus, Web of Science. Random-effects models addressed high heterogeneity, and subgroup analyses examined temporal trends, regional differences, and healthcare settings. Meta-regression explored sources of heterogeneity for both severity and case fatality rate, adjusting for study year, region, and setting. Results: We included a total of 19 study reports. The pooled severity rate among 3,280 confirmed cases was 39.47% (95% confidence interval [CI] 29.11–50.86). Case fatality rates (CFRs) were 1.70% (95% CI 0.72–3.95) among 3152 suspected cases and 2.46% (95% CI 0.65–8.85) for 2239 confirmed cases. Meta-regression revealed that study year, region and setting were significant sources of heterogeneity of case fatality rates among confirmed mpox cases. Conclusion: Mpox continues to impose a substantial burden in the DRC, with a high severity and moderate mortality rates. Targeted interventions, including vaccination in high-risk areas, community education, and healthcare system strengthening are warranted.